Zeller N, Busch C-J, Schafhausen P, Knecht R, Möckelmann N
Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
HNO. 2014 Nov;62(11):787-92. doi: 10.1007/s00106-014-2927-0.
The treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) requires exceptional interdisciplinary cooperation within the treatment team, as many factors need to be taken into account to come to an adequate treatment decision. Most of these patients need to be treated in a palliative concept, as comorbidities and prior oncologic treatment limit the treatment options. Inhibitors of epidermal growth factor receptor (EGFR) in combination with platinum and 5-fluorouracil (5-FU) may be considered as standard. However, survival rates are poor and new therapeutic approaches and substances are therefore tested continuously. At the annual meeting of the American Society of Clinical Oncology (ASCO) in 2014, numerous studies on first- and second-line treatment of R/M-HNSCC were presented. A selection is discussed in this paper, including a report about the combined therapy of cetuximab with established chemotherapies, new results from protocols including small molecules and investigations of mTOR inhibitors.
复发性或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者的治疗需要治疗团队内部进行特殊的多学科协作，因为做出恰当的治疗决策需要考虑诸多因素。这些患者中的大多数需要采用姑息治疗方案，因为合并症和既往肿瘤治疗限制了治疗选择。表皮生长因子受体（EGFR）抑制剂联合铂类和5-氟尿嘧啶（5-FU）可被视为标准治疗方案。然而，生存率较低，因此一直在不断试验新的治疗方法和药物。在2014年美国临床肿瘤学会（ASCO）年会上，展示了大量关于R/M-HNSCC一线和二线治疗的研究。本文将讨论其中一部分研究，包括西妥昔单抗与既定化疗联合治疗的报告、包含小分子的方案的新结果以及mTOR抑制剂的研究。
